A recent study suggests that SGLT2 drugs – now shown to dramatically improve cardiovascular and renal outcomes in a wide variety of patients – have a higher incidence of euglycemic DKA than previously thought. If pharmacists see more of this ADR, how do we treat appropriately – especially when a patient’s sugars may not be very high?
This episode is accredited for CPE. For CE details and to claim credit, click here: https://bit.ly/3gy7F4O
See omnystudio.com/policies/listener for privacy information.
